Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus.

ABSTRACT: Several investigational agents are under evaluation in systemic lupus erythematosus (SLE) clinical trials but quantitative frameworks to enable comparison of their efficacy to reference benchmark treatments are lacking. To benchmark SLE treatment effects and identify clinically important covariates, we developed a model-based meta-analysis (MBMA) within a latent variable model framework for efficacy end points and SLE composite end point scores (BILAG-based Composite Lupus Assessment and Systemic Lupus Erythematosus Responder Index) using aggregate-level data on approved and investigational therapeutics. SLE trials were searched using PubMed and www.clinicaltrials.gov for treatment name, SLE and clinical trial as search criteria that resulted in four data structures: (1) study and investig

SUBMITTER: Goteti K 

PROVIDER: S-EPMC10864929 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature